ArticleFrontiers in pharmacology2020

Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.

Pushpendra Goswami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.